Sign up to save your podcasts
Or
Share S2 Ep48: Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
S2 Ep48: Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment
Thanks for your interest in this podcast. Please read this important program information before listening.
Episode Description
In this podcast, experts Joyce O’Shaughnessy, MD; Hope S. Rugo, MD; and Matthew P. Goetz, MD, discuss innovations in targeting TROP2 in triple-negative breast cancer treatment.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate efficacy and safety data from clinical trials evaluating TROP-2–targeted antibody-drug conjugates (ADCs) for triple-negative breast cancer (TNBC)
Acknowledgment of Educational Grant Support
This activity is supported by an educational grant from Gilead Sciences, Inc.
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions on How to Receive Credit
You may immediately download your certificate.
Chair
Joyce O’Shaughnessy
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Director, Breast Cancer Research Program
Texas Oncology
US Oncology
Dallas, TX
Disclosures: Consultant: AbbVie, Agendia, Amgen, Aptitude Health, AstraZeneca, BioNTech, Byondis, Carrick Therapeutics, Daiichi Sankyo, DAVA Oncology, Eisai, Eli Lilly and Company, Fishawack Health, G1 Therapeutics, GSK, Genentech, Genzyme, Gilead Sciences, Loxo Oncology, Merck, Novartis, Ontada, Pfizer, Pierre Fabre, Puma Biotechnology, Roche, Samsung Bioepis, Sanofi, Seagen, Stemline Therapeutics, Taiho Oncology, Verily
Faculty
Matthew P. Goetz, MD
Erivan K. Haub Family Professor of Cancer Research Honoring Richard F. Emslander, MD
Professor of Oncology and Pharmacology
Enterprise Deputy Director, Translational Research
Mayo Clinic
Rochester, MN
Disclosures: Consulting fees: AstraZeneca, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Ltd, BeiGene USA, Biotheranostics, Biotheryx, eChinaHealth, EcoR1, Eli Lilly & Co, Engage Health Media, Genentech, Incyclix, Laekna, Lilly, Novartis, RNA Diagnostics, Seattle Genetics, Sermonix, Stemline Therapeutics, TerSera Therapeutics; Grant funding: AstraZeneca, ATOSSA Therapeutics, Biotheryx, Lilly, Loxo, Pfizer, Sermonix, SimBioSys; Travel support: Lilly; CME activities: AXIS, BroadcastMed, DAVA Oncology, IDEOlogy Health, MJH Life Sciences, PeerView, Physicians’ Education Resource, Research to Practice, Total Health Conferencing
Hope S. Rugo, MD, FASCO
Director, Women’s Cancers Program
Division Chief, Breast Medical Oncology
Professor, Department of Medical Oncology & Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, CA
Professor Emeritus, UCSF
Disclosures: Adviser: Ambryx, Chugai, OBI Pharma, Puma; Consultant: Ambryx, Chugai, OBI Pharma, Puma; Researcher: AstraZeneca, Daiichi Sankyo, F. Hoffman-La Roche AG/Genentech, Gilead Sciences, Lilly, Merck & Co, Mylan, Napo, Novartis Pharmaceuticals Corporation, Pfizer, Sanofi, Stemline Therapeutics
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
To learn more about this topic, including information on integrating TROP2-targeted ADCs into individualized treatment plans and addressing disparities in care among diverse populations of patients with TNBC, go to https://www.gotoper.com/ibc25trop2tnbc-activity
Release Date
August 28, 2025
Expiration Date
August 28, 2026
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.
View all episodes
By PER® SpectivesThanks for your interest in this podcast. Please read this important program information before listening.
Episode Description
In this podcast, experts Joyce O’Shaughnessy, MD; Hope S. Rugo, MD; and Matthew P. Goetz, MD, discuss innovations in targeting TROP2 in triple-negative breast cancer treatment.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate efficacy and safety data from clinical trials evaluating TROP-2–targeted antibody-drug conjugates (ADCs) for triple-negative breast cancer (TNBC)
Acknowledgment of Educational Grant Support
This activity is supported by an educational grant from Gilead Sciences, Inc.
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions on How to Receive Credit
You may immediately download your certificate.
Chair
Joyce O’Shaughnessy
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Director, Breast Cancer Research Program
Texas Oncology
US Oncology
Dallas, TX
Disclosures: Consultant: AbbVie, Agendia, Amgen, Aptitude Health, AstraZeneca, BioNTech, Byondis, Carrick Therapeutics, Daiichi Sankyo, DAVA Oncology, Eisai, Eli Lilly and Company, Fishawack Health, G1 Therapeutics, GSK, Genentech, Genzyme, Gilead Sciences, Loxo Oncology, Merck, Novartis, Ontada, Pfizer, Pierre Fabre, Puma Biotechnology, Roche, Samsung Bioepis, Sanofi, Seagen, Stemline Therapeutics, Taiho Oncology, Verily
Faculty
Matthew P. Goetz, MD
Erivan K. Haub Family Professor of Cancer Research Honoring Richard F. Emslander, MD
Professor of Oncology and Pharmacology
Enterprise Deputy Director, Translational Research
Mayo Clinic
Rochester, MN
Disclosures: Consulting fees: AstraZeneca, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Ltd, BeiGene USA, Biotheranostics, Biotheryx, eChinaHealth, EcoR1, Eli Lilly & Co, Engage Health Media, Genentech, Incyclix, Laekna, Lilly, Novartis, RNA Diagnostics, Seattle Genetics, Sermonix, Stemline Therapeutics, TerSera Therapeutics; Grant funding: AstraZeneca, ATOSSA Therapeutics, Biotheryx, Lilly, Loxo, Pfizer, Sermonix, SimBioSys; Travel support: Lilly; CME activities: AXIS, BroadcastMed, DAVA Oncology, IDEOlogy Health, MJH Life Sciences, PeerView, Physicians’ Education Resource, Research to Practice, Total Health Conferencing
Hope S. Rugo, MD, FASCO
Director, Women’s Cancers Program
Division Chief, Breast Medical Oncology
Professor, Department of Medical Oncology & Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, CA
Professor Emeritus, UCSF
Disclosures: Adviser: Ambryx, Chugai, OBI Pharma, Puma; Consultant: Ambryx, Chugai, OBI Pharma, Puma; Researcher: AstraZeneca, Daiichi Sankyo, F. Hoffman-La Roche AG/Genentech, Gilead Sciences, Lilly, Merck & Co, Mylan, Napo, Novartis Pharmaceuticals Corporation, Pfizer, Sanofi, Stemline Therapeutics
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
To learn more about this topic, including information on integrating TROP2-targeted ADCs into individualized treatment plans and addressing disparities in care among diverse populations of patients with TNBC, go to https://www.gotoper.com/ibc25trop2tnbc-activity
Release Date
August 28, 2025
Expiration Date
August 28, 2026
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.